Anti-Inversion Legislation May Impact Noninverted PE Deals
Corporate inversions have been the target of regulatory or statutory tax proposals for many years. However, the recently attempted combination of Pfizer and AstraZeneca received prompt and more far-reaching attention in...To view the full article, register now.
Already a subscriber? Click here to view full article